Us Allergy Diagnostics Therapeutics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The U.S. allergy diagnostics and therapeutics market encompasses products and services used to identify and treat allergic diseases, including respiratory, food, and drug-related allergies. In 2024, the market was valued at approximately $10.86 billion and is projected to reach roughly $16.13 billion by 2030, expanding at a compound annual growth rate of 6.8%.

• •North America holds approximately 36.62% of global market share as of 2025, making it the leading regional market
• •The broader global allergy diagnostics and therapeutics market is valued at roughly $38.1 billion
• •The U.S. segment spans two primary categories: diagnostics (in-vivo skin tests, in-vitro blood assays) and therapeutics (immunotherapy, biologics, antihistamines)

Increasing prevalence of allergic diseases across food, respiratory, and drug categories is the primary catalyst for market expansion. Growing clinical awareness and improved screening protocols are driving earlier diagnosis and greater treatment uptake.

• •Advancements in in-vivo and in-vitro diagnostic technologies are expanding testing accuracy and accessibility
• •Strong U.S. healthcare infrastructure and well-established regulatory pathways support product commercialization
• •Higher allergy prevalence, particularly in pediatric and geriatric populations, is widening the addressable patient base

The market is segmented by product type into diagnostics and therapeutics, and further divided by allergen type including food, inhaled, and drug allergens. North America leads globally, supported by its advanced healthcare system and high disease burden.

• •Diagnostics and therapeutics are the two core segments, with diagnostics capturing significant share due to screening demand
• •Food, inhaled, and drug allergen categories represent the primary segmentation by allergy trigger type
• •North America's leadership position is reinforced by regulatory maturity and high per-capita healthcare spending

Who are the notable companies in the industry?

I can't write that section from this research. The text you provided contains only unrelated content: U.S. Bank promotional material, USA.gov navigation pages about government benefits, and generic banking descriptions. There is no information about allergy diagnostics, therapeutics, or any of the named companies (Thermo Fisher Scientific, Danaher, HollisterStier Allergy, NEOGEN Corporation, Minaris Medical America, HYCOR Biomedical, ACON Laboratories). To produce an accurate Competitive Landscape section with factual descriptors for each company, I would need source material that actually discusses these firms, their products (e.g., ImmunoCAP, specific IgE assays, allergen extracts), their roles in allergy testing vs. immunotherapy, and their positioning in the North American market. What would help: - The actual market research report's competitive analysis chapter - Company profiles or vendor section from the source - Any passages describing product portfolios, test menus, or immunotherapy offerings Once you share relevant research text, I can draft a 150-210 word analytical section that names the verified players with descriptors drawn strictly from that material, no invented figures or companies.

• •The industry is moderately consolidated, with several large diversified healthcare firms co-existing alongside niche specialty diagnostic producers
• •Technology routes split between in-vivo methodologies (skin prick and patch testing) and in-vitro immunoassay platforms (ELISA, ImmunoCAP, component-resolved diagnostics)
• •Manufacturing and R&D capacity is geographically concentrated in North America and Europe, reflecting regulatory access and skilled workforce requirements

What are the recent trends and outlook?

The market is expected to sustain its 6.8% CAGR trajectory through 2030, underpinned by rising allergy incidence and evolving diagnostic capabilities. Continued innovation in precision diagnostics and biologic therapeutics is likely to reshape competitive dynamics over the forecast period.

• •Component-resolved diagnostics and molecular allergy testing are emerging as high-growth subsectors within the testing category
• •Biologic therapeutics targeting specific allergic pathways are gaining clinical adoption, particularly for severe and chronic conditions
• •Point-of-care and at-home testing solutions represent a structural shift toward decentralized allergy care models